HUTCHMED has started a global clinical trial for HMPL-A251, a first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) from its next-generation platform, with the potential to transform treatment for patients with solid tumours. Unlike traditional toxin-based treatments that often cause harsh systemic side effects, HUTCHMED’s ATTC combines an antibody with a targeted blocker to deliver dual mechanisms of action directly into cancer cells, thereby improving efficacy while enhancing safety.

The first patients started treatment in December 2025 and the Phase I/IIa clinical trial is now underway at sites in the US and China. Early lab results beat standalone components, bringing hope to patients battling these tough cancers.  

For 75 years, Superior Refinery has powered communities and industries, standing as a cornerstone of Wisconsin’s energy landscape. Since opening in 1951, the refinery has grown alongside the region, supported by generations of employees who take pride in keeping it running safely and reliably. Over the years, the refinery has continued to thrive, embracing innovation and sustainability. The facility now produces approximately 740 million gallons of energy products every year and remains one of North America’s top asphalt suppliers. Cenovus continues to deliver key products across the US through the superior power of its refinery.  

When a dutiful Hong Kong son steps away from a parent-blessed path, the motivation must be strong. But Nelson Ng – now Dr Ng – made a discovery deep within himself that sparked a drastic pivot in his life’s direction.
Full Article

A fire at a Hong Kong housing complex devastated hundreds of lives and homes. The CKHH family moved quickly to bring support to those in need. Watsons, PARKnSHOP, Fortress and Watsons Water delivered essential supplies and set up Care Service Stations. They also donated home appliances, home essentials and personal care products to the affected families as they move into transitional housing. HTHKH’s 3Shops offered free backup phones, portable chargers, SIM cards and 5G services. The HK Electric Service Team provided on-site help. The Li Ka Shing Foundation promptly distributed HK$30 million to charities to provide immediate relief and pledged HK$50 million for recovery efforts, aiding families to rebuild their lives.

Cenovus Energy is firing on all cylinders as a record-setting quarter preceded its acquisition of MEG Energy, a Canadian oil producer. The deal adds approximately 110,000 barrels of daily production to Cenovus’ portfolio. In the third quarter, Cenovus recorded its highest ever upstream oil production (almost 833,000 barrels of oil equivalent per day before the MEG acquisition) and downstream throughput, and a dramatic rise in profit compared to 2024, rising to C$1.29 billion.  

CK Life Sciences is bolstering and accelerating the development of its cancer therapeutic pipeline. A merger between its subsidiary, Polynoma, and TransCode Therapeutics, a Nasdaq-listed clinical-stage biopharmaceutical company, is expected to create possible synergies, enhance capabilities and diversify the pipeline. This move is also anticipated to open new doors to capital, which will potentially speed up the development of Polynoma’s melanoma cancer vaccine candidate and unlock its value.

HUTCHMED’s Shanghai facility just completed the first nationwide shipment of Tazemetostat, the world’s first-in-class EZH2 inhibitor for follicular lymphoma patients. The rollout from the Zhangjiang base brings a critical new treatment option to adults with relapsed or refractory follicular lymphoma. Being the first and only EZH2 inhibitor approved by China’s National Medical Products Administration, Tazemetostat has shown a 63.6% objective response rate in Chinese patients. The launch highlights HUTCHMED’s scientific acumen and ability to navigate regulatory and distribution hurdles to deliver a breakthrough therapy at scale. For patients who have exhausted all other options, it represents renewed hope.

ESDlife recently unveiled Welloft, a premium wellness platform targeting Hong Kong’s health-conscious consumers. The name, a combination of “well” and “loft”, represents a dedicated space for wellness – on board are 20 trusted medical service providers, positioning ESDlife as Hong Kong’s wellness concierge.

The timing couldn’t be better. With interest in preventative healthcare on the rise, Welloft promises to simplify the complex medical landscape. Users can now access physical and mental wellness services under one digital roof. For a city that takes health seriously, Welloft is an essential tool for maintaining everyone’s well-being.  

Canada’s Cenovus plays a pivotal role in the energy sector. Major projects in Alberta and Newfoundland and Labrador are taking steps forward to increase production and strengthen the energy sector, continuing CKHH’s contribution to the industry, ongoing since 1987.
Full Article

The CK Group has always been a supporter of the Community Chest of Hong Kong. Its Cheung Kong Donation Hotline is backing the Community Chest Rainbow Fund for the 20th time. This year, the CK Group and the Li Ka Shing Foundation are continuing their powerhouse philanthropic collaboration with their signature “double match” magic. The duo chip in HK$2 for every HK$1 given, tripling the impact of public donations.

CKDelta is an AI software business within the CK Hutchison Group. Its product, ∆Priority, shows technology can have a heart. It uses advanced machine learning to identify vulnerable customers, such as the fuel poor, who can benefit from programmes like the Priority Services Register (PSR) and Leaving No One Behind network. By combining over 30 datasets – including smart metre data, payment history, telecoms and socio-economic indicators – it creates a unified vulnerability profile for each customer. The models are continuously retrained to reflect real-world changes and ensure accuracy.

This AI-driven approach has identified over 400,000 vulnerable customers and improved CKDelta’s engagement strategy effectiveness by 30%. ∆Priority enables proactive, personalised support at scale, setting a new standard for ethical, data-led customer care.  

CK Life Sciences (CKLS) has filed an Original Grant Patent application in Hong Kong and a provisional patent application in the US for its novel cancer vaccines targeting TROP2.

In preclinical studies, the TROP2 cancer vaccines have demonstrated impressive tumor growth inhibition in triple-negative breast cancer (“TNBC”) and colorectal cancer. The results of animal studies involving TNBC have been encouraging, with mouse models showing 100% tumor growth inhibition after receiving the TROP2 cancer vaccine.

CKLS looks forward to advancing its TROP2 cancer vaccine expeditiously into clinical trials to benefit patients and believes it holds significant potential in preventing cancer recurrence.

HUTCHMED recently celebrated the approval of its innovative drug combination of fruquintinib and sintilimab for treating endometrial cancer in China. The grand launch event in Shanghai brought together leading experts to discuss the latest advancements in gynaecological cancer treatment. This milestone highlights the expansion of fruquintinib’s use beyond its initial indication for colorectal cancer, underscoring HUTCHMED’s commitment to biopharmaceutical innovations to transform patients’ lives in China and around the world. The new treatment offers hope and more options for women living with cancer, setting new standards for the diagnosis and treatment of gynaecological cancer.  

Greene King partner The Hand & Flowers has once again been awarded two stars in the “Michelin Guide Great Britain & Ireland 2025”, making it Great Britain’s only two Michelin-starred pub. Located in the ancient town of Marlow in Buckinghamshire, The Hand & Flowers was opened in 2005, and Greene King has just celebrated the 20th anniversary of its partnership with the pub’s team earlier this year. The Hand & Flowers is operated by celebrity chef Tom Kerridge, who is described in the Michelin guide as “the king of British pub dining”. After the pub received one Michelin star in just its second year of operation, it retained its star until receiving a second star in 2012. It has maintained its two-star status every year since. Greene King is an integrated brewer and pub retailer under CK Asset Holdings, operating around 2,600 pubs, restaurants and hotels across England, Wales and Scotland.

HUTCHMED’s ORPATHYS® (savolitinib) has been approved by the China National Medical Products Administration (NMPA) as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET ex14 skipping alteration. This approval means that both newly diagnosed and previously treated patients can now access this targeted therapy.

In a large clinical trial, ORPATHYS® showed strong results, helping more than 60% of first-time patients see their tumours shrink. Even those who had previously tried other treatments saw positive effects.

With AstraZeneca as a partner, HUTCHMED is also looking to expand ORPATHYS®’ usage to help even more people with this form of lung cancer.  

CK Life Sciences’ wholly-owned subsidiary, Vancouver-based WEX Pharmaceuticals, has merged with Nasdaq-listed Virios Therapeutics. The new company is called Dogwood Therapeutics (NASDAQ: DWTX). The merger enables WEX to tap into the US capital markets and to benefit from a strong management team to accelerate the development of its lead product, Halneuron®, for treatment of moderate-to-severe pain conditions caused by cancer and chemotherapy. CKLS now owns 15.9% of the common shares of the combined venture, plus a series of convertible preferred shares, which upon conversion will make CKLS the majority shareholder.

HUTCHMED has hit another milestone with the addition of ELUNATE^® (fruquintinib) to the Hong Kong Hospital Authority Drug Formulary under the Special Drug category with full subsidy. The enlistment came in 11 months from filing for market authorisation to being enlisted in the Special Drug category.

HUTCHMED has also launched a cutting-edge research and development (R&D) centre at the Hong Kong Science Park. The new facility will specialise in a number of areas including translational research and AI-driven drug discovery, marking a new chapter in accelerating its global R&D of cancer treatment therapies.  

HUTCHMED’s FRUZAQLA® (fruquintinib) has secured approval in the European Union, UK and Switzerland to treat patients with metastatic colorectal cancer (CRC). This is a significant advancement in the treatment of CRC and means that patients have a new option to receive oral targeted therapy if chemotherapy and other treatments fail.

In Japan, regulators have given the green light to Takeda, HUTCHMED’s partner, to manufacture and market FRUZAQLA® for patients with previously treated metastatic CRC. FRUZAQLA® is the first novel targeted therapy in Japan to be approved for CRC in over a decade.  

Cenovus Energy’s Asia Pacific team is marking a decade of successful operations at the Liwan gas project, the first deepwater gas venture in offshore China. Located southeast of Hong Kong, Liwan has delivered around 1,256 billion cubic feet of gas to date since kicking off production in March 2014. Last year, the Liwan 3-1 field hit a major milestone, surpassing one trillion standard cubic feet in gas sales.

The 10-year celebration at Zhuhai Gaolan Terminal honoured the Liwan team’s ingenuity and diligent attention to safety while they continue to deliver responsible operations.  

Safety engineers at CKHH companies around the world are innovating by using flyers and rollers to improve quality, lower costs and increase the frequency of safety inspections.
Full Article

HUTCHMED hit a milestone with the Hong Kong marketing approval of ELUNATE® (fruquintinib), a drug to help treat metastatic colorectal cancer. This groundbreaking achievement makes it the first medicine to have passed the innovative “1+” mechanism by the government, offering a ray of hope to patients across the SAR.

As the first oral targeted therapy endorsed in Hong Kong for metastatic colorectal cancer (regardless of biomarker status or prior types of therapies) in nearly a decade, ELUNATE® is a game-changer for patients.

Fruquintinib’s success extends beyond Hong Kong! In addition to approvals in mainland China, Macau SAR and the United States, the future looks brighter for those battling colorectal cancer in Hong Kong and beyond.  

GAMECO has wrapped up a successful chapter with the completion of Lufthansa’s Winter Heavy Maintenance Programme 2023–2024, where it meticulously serviced 12 Airbus A350 and A330 aircraft, ensuring top-notch quality every step of the way.

Operating from its main base in Guangzhou, each aircraft underwent rigorous maintenance checks, guaranteeing optimal performance and safety for Lufthansa’s fleet. GAMECO is immensely grateful and proud that one of the world’s leading premium airlines has entrusted their most modern long-range aircraft to the company.

HUTCHMED has joined a prestigious line-up of 60 enterprises in partnership with the Hong Kong-Shenzhen Innovation and Technology Park to bolster fresh research and development initiatives. Part of this move includes investigating the creation of R&D operations in Hong Kong.

A commitment to innovation and growth bolsters the strategic advantages of this fruitful partnership, which also benefits from Hong Kong’s low tax rates and highly open capital market.

HUTCHMED looks forward to embarking on this ambitious partnership, which is sure to drive medical advancements and have a global impact on healthcare.

Sailing through academic waters just got smoother with Cenovus Energy’s scholarship programmes, which provide support to bright young minds in the US and Canada. Their Indigenous scholarships and STEM scholarships award recipients with $5,000 each (CAD and USD), along with development opportunities to help students thrive in their future careers.

These scholarships aim to remove barriers for students so that they can focus on their studies, develop their skills, broaden their networks and identify job opportunities for the future.  

In the world of health supplements, it used to be enough to offer just vitamins and minerals. But now, consumers demand nootropics and other new categories of supplements that improve mental health, mental performance and achieve “beauty from within”.
Full Article

Those suffering from metastatic colorectal cancer will soon have another option that could improve their survival rates and extend their lives. HUTCHMED’s partner, global pharmaceutical firm Takeda, has obtained approval from the US Food and Drug Administration to make FRUZAQLA™ (fruquintinib) available on the US market.

The drug has been approved for use in patients as part of a treatment protocol that gives them another chance when other treatments such as chemotherapy have proven ineffective. The development partnership with Takeda is part of a broader global partnership strategy. Achieving this watershed will trigger the delivery of sales royalties as well as a milestone payment as part of a deal that will total up to US$1.13 billion.  

Scientists are making incredible progress in using vaccines to combat cancer, bringing hope for improved cancer treatments in the future. Researchers at CK Life Sciences are developing vaccines that can slow down the growth and spread of cancer or prevent its recurrence after surgery.

One of their promising vaccines targets two proteins, PD-L1 (programmed death ligand 1) and PRAME (preferentially expressed antigen in melanoma), which are involved in promoting cancer. Normally, the immune system uses T cells to attack cancer cells, but PD-L1 puts the brakes on T cells, preventing them from doing their job. PRAME, on the other hand, promotes cancer cell growth and spread.

CK Life Science’s PD-L1/PRAME dual-targeting vaccine works by stimulating the immune system to produce T cells that can specifically kill cancer cells that have PD-L1 and/or PRAME. It also triggers the production of antibodies that can block PD-L1, allowing the T cells to attack cancer cells more effectively. Additionally, antibodies against PRAME further enhance the killing of cancer cells.

CK Life Sciences presented their innovative research on this vaccine at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, showcasing its potential for treating liver cancer.  

ESDlife’s WeVow lit a fire at the Spark Awards 2023 to win two Gold awards for “Best Promotion Strategy” and “Best Use of Mobile/App”. WeVow is a wedding app that uses AI and data analyses to make life easier for stressed-out couples working on making their big day the best day.

WeVow and a staff engagement app, We+, along with various client projects, have racked up the awards all year long, including the Hong Kong Institute of Marketing Triple Crown Award. The We+ app won Human Resources Online magazine’s Gold for the “Best HR Digital Transformation Strategy”. These are just the highlights of over 15 awards won from those listed plus the Hong Kong Wireless Technology Industry Association, the DigiZ Awards, MOB-Ex Awards, Loyalty and Engagement Awards, Employee Experience Awards and HR Distinction Awards.

Cenovus is contributing C$100,000 to the building of a children’s park. This will provide an inclusive space for residents and visitors alike to interact and build positive experiences in the town of Lamont, Alberta.

“Tawâw” means “Come in, you’re welcome” or “There is always room for one more” in the language of the local Indigenous people, the Cree. The development is part of Cenovus’ commitment to supporting healthy, safe and resilient communities. There will also be several Indigenous elements, including an orange footbridge to emphasise the importance of a safe space for children – the colour orange reflects that every child matters and represents Orange Shirt Day, a Canadian movement established in response to past injustices visited on Indigenous people and especially their children. Indigenous youth artists will also be invited to decorate the space.  

Shanghai Hutchison Pharmaceuticals Ltd is passionate about bringing education to children in rural communities in China. It recently built its 84th library in the country. This repository of learning is in Chengkou, a rural county in the mountains of southwest China and far from the madding crowd. Volunteers from the company were led on this expedition by company president Zhou Junjie.

Zhou made good use of his knowledge of Chinese medicine by conducting a course on traditional Chinese medicines to introduce the concept to children and perhaps inspire them to become healthcare practitioners and to learn more about their Chinese heritage.

Lake Superior is the greatest of the Great Lakes, the huge inland freshwater oceans that stretch into the heart of North America. They are a vital waterway, and at their western extremity lies the Duluth Marine Terminal, fuelled and operated by the Cenovus Superior Refinery. This crucial gateway brings goods into the American heartland at the border of two states, Minnesota and Wisconsin.

Freight moved by water is one of the most energy-efficient forms of transport. The terminal also serves as a major refuelling port for ships carrying essential products such as limestone, grain, cement, salt, wind turbines and other cargo. It provides economic support as a transit port for the region and as a local employer is a vital part of the mid-West economy.  

CK Life Sciences’ Dominion Salt has been a pioneer and industry leader in providing high-quality salt products to customers worldwide for the past seven and a half decades. Dominion Salt started salt production at Lake Grassmere on the northern end of South Island and never looked back. Its Lake Grassmere salt field was New Zealand’s first and remains its only salt field today. Dominion Salt’s diamond anniversary sees it providing a wide range of salt products, from table salt for people and salt licks for animals to pharmaceutical grade sodium chloride.

HUTCHMED has passed key milestones to be accepted for review for use in the US and Europe. The fruquintinib New Drug Application has been accepted by the US Food and Drug Administration (FDA). The FDA has also granted priority review, with the Prescription Drug User Fee Act (PDUFA) date set for 30 November 2023. The Market Authorization Application in Europe has also been validated and accepted for regulator review by the European Medicines Agency. Results of the Phase III FRESCO‑2, a key study that supported the regulatory submissions, were published in The Lancet, one of the world’s most prestigious and well-respected medical journals.  

Shanghai Hutchison Pharmaceuticals has received approval from Health Canada to directly export their Danning Tablets to Canada. The product will be marketed as a licensed natural product in Canada under the brand name Biliflow. It marks not only a step forward for Shanghai Hutchison Pharmaceuticals but also the internationalisation and modernisation of traditional Chinese medicine.  

HUTCHMED has come to a licensing agreement with global pharmaceutical giant Takeda Pharmaceutical to further the global development, commercialisation and manufacture of fruquintinib outside of China. A US$400 million upfront payment and additional potential milestone payments could reach US$1.13 billion upon achieving regulatory, development and commercial sales milestones.  

Canada has always been, and continues to be, a hot destination for immigrants. Cenovus Energy is supporting their resettlement with a C$450,000 grant to local non-governmental organisation (NGO) Immigrant Services Calgary (ISC). The city is home to over 400,000 immigrants and refugees and the strategic partnership with ISC will help direct immigrants to over 50 newcomer-serving partner organisations to help them with employment, education, health and more. Beyond the connection to services, the grant will also support the Immigrants of Distinction Awards gala that celebrates the contribution of immigrants to a strong and prosperous Canada.  

HUTCHMED’s fruquintinib is now targeting second-line gastric cancer. A Phase III study, involving 703 patients, has shown a statistically significant impact in improving progression-free survival (PFS) when combined with another drug, paclitaxel. PFS is the length of time during and after the treatment of a disease wherein a patient lives with the disease but it does not get worse.

HUTCHMED has recently completed patient enrolment of ESLIM-01, the Phase III clinical trial of sovleplenib for the treatment of immune thrombocytopenia (ITP), an autoimmune disorder that can lead to increased risk of bleeding. ITP can often be serious and can have a significant, multifaceted impact on patients’ health and quality of life. Patients often become resistant to treatment over time and new treatment options are desperately needed. The drug has been granted Breakthrough Therapy Designation for ITP in China. It is also being studied for use in indolent non-Hodgkin’s lymphoma and multiple subtypes of B-cell malignancies.

PharusDx, a CK Life Sciences and CK Hutchison investee, is developing a test that would provide fast, accurate diagnosis of not one but multiple types of cancer – all from a single blood sample. And it is using AI to do it.
Full Article

HUTCHMED’s global Phase III registration trial of its colorectal cancer-fighting drug, fruquintinib, aims to gain the regulatory approvals needed to bring it to cancer patients around the world. A 14-country study is the next step in bringing new options to doctors and new hope to families struggling with cancer.
Full Article

Patient access to novel treatments just got easier in parts of China. HUTCHMED’s surufatinib (SULANDA® in China) has been approved in the Macau Special Administrative Region. This drug has benefited over 12,000 patients with neuroendocrine tumours in China.

HUTCHMED’s first in-licensed product tazemetostat (TAZVERIK®) has been approved for use in Hainan Boao Lecheng International Medical Tourism Pilot Zone under the Clinically Urgently Needed Imported Drugs scheme. TAZVERIK® is a first-in-class EZH2 inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of certain patients with follicular lymphoma and advanced epithelioid sarcoma, a type of blood cancer and soft-tissue cancer, respectively.  

GAMECO, operating out of Guangzhou Baiyun International Airport since 1989, has signed two major agreements with the world-leading aircraft manufacturer, Boeing. A five-year contract will see them cooperate on the first integrated materials management partnership in Mainland China. Boeing will provide demand planning, on-site personnel and logistics services to support GAMECO’s operations to optimise materials purchase and inventory costs.

The other agreement will see the firms work together to expand their cooperation to convert passenger aircraft to freighters to match growing demand for cargo capacity, with B737-800 Boeing Converted Freighters (BCFs) and B767-300 BCFs being adapted. In fact, GAMECO just celebrated re-delivery of the first Boeing B767-300 BCF in Mainland China last month. Boeing forecasts demand for over 1,720 freighter conversions in the next 20 years.  

hutchgo.com celebrates 20 years of transporting people to their heart’s desire. Formerly known as Hutchison-Priceline at inception in 2002, they continue to provide best-in-class service and assistance to travellers with all their heart. Here’s to the next 20 years!

Authorities in the Macau Special Administrative Region have approved the commercialisation of ELUNATE® (fruquintinib). ELUNATE® gained its first approval in Mainland China by the National Medical Products Administration (“NMPA”) in September 2018 for the treatment of metastatic colorectal cancer. It is estimated that more than 40,000 patients have benefited from this novel treatment since its launch. It is the first homegrown innovative oncology drug to be marketed in Macau based on NMPA approval.

A new wave of HUTCHMED innovation is also on the way. In January 2022, sovleplenib was granted Breakthrough Therapy Designation by the NMPA. The designation allows accelerated development of new drugs that treat life-threatening diseases or serious conditions which lack effective treatment options. Sovleplenib has demonstrated encouraging results in patients with immune thrombocytopenia (“ITP”), an autoimmune bleeding disorder that can often have a significant, multifaceted impact on patients’ health and quality of life. It is now being studied in a China Phase III trial on ITP, along with additional studies on lymphoma ongoing in China, the US and Europe.  

ESDlife honours those entrusted with the most important day in the lives of young couples in love. Bridal Award 2021 recognised those companies that delivered the utmost in wedding excellence in 2021, ensuring the “big day” was also a perfect one. Thirty-eight awards were presented to outstanding brands and service providers in Hong Kong.

China’s National Reimbursement Drug List aims to make life-saving drugs accessible to citizens in Mainland China and has expanded the number of HUTCHMED medicines on the list. The latest to be included is SULANDA® (surufatinib), following its approval for the treatment of advanced pancreatic neuroendocrine tumours. This latest update of the list also renewed ELUNATE® (fruquintinib), first included in 2020, for the treatment of metastatic colorectal cancer.  

Guangzhou Aircraft Maintenance Engineering Company (GAMECO) opened a new aircraft maintenance facility covering an area of over 98,000 square metres, with a roof big enough to accommodate six wide-body and five narrow-body aircraft under its capacious canopy. This increase in capacity will strengthen the Guangzhou airport economic zone as an important national centre for aircraft maintenance, helping China Southern Airlines’ fleet and supporting other customers in the region.  

HUTCHMED is now a constituent stock in the FTSE Russell’s Global Equity Index Series (GEIS), including FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The GEIS monitors more than 16,000 stocks in over 70 countries representing 98% of global market cap, making it a key indicator of global stock market direction.  

ESDlife had a very successful awards season in 2020 during a challenging year for the retail, public services, banking and finance, and insurance industries. The company won a Gold Award for Best AI Solution at the DigiZ Awards 2020 and a Gold Award for Best Loyalty Programme at The Loyalty and Engagement Awards 2020. It also won a range of other awards in mobile and apps, customer loyalty, fintech, design and retail.

HUTCHMED is the new brand for the innovative biopharmaceutical business formerly known as Hutchison China MediTech. The company recently launched a successful listing on the Stock Exchange of Hong Kong (adding to its London AIM and Nasdaq presence), under the venerable stock code 13, which had been held by Hutchison Whampoa. It is now included in over 10 indexes including the Hang Seng Composite Index, the main board listing in Hong Kong, in addition to the Hang Seng Healthcare Index, and the Hang Seng Hong Kong-Listed Biotech Index. Mainland investors also have access to the stock through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programmes.  

Orpathys® (savolitinib, for lung cancer) and Sulanda® (surufatinib, for neuroendocrine tumours) have both been approved for use and then launched in Mainland China this year. Both drugs are unique, novel therapies created by HUTCHMED. Orpathys® is the only targeted medicine approved for these biomarker-selected patients in the Mainland. Sulanda®’s two recent approvals make it the first-ever drug launched to counter neuroendocrine tumours regardless of tumour origin, and approvals are also being sought in major jurisdictions such as the US and Europe.  

Guangzhou Aircraft Maintenance Engineering Company (GAMECO) has expanded its aircraft maintenance operations to the newest airport in the nation’s capital, Beijing. GAMECO has recently been awarded approval from the Federal Aviation Administration and the European Aviation Safety Agency to conduct line maintenance and heavy maintenance. GAMECO’s operations hangar is Asia’s largest, and can hold up to five wide-body plus three narrow-body aircraft (or 12 narrow-body aircraft) at the same time.